ERBB2 and breast carcinoma: In metastatic HER2-positive breast cancer, the combination of a PD-1/PD-L1 inhibitor plus an anti-HER2 agent has been first explored in the single-arm, multicenter, phase 1b/2 study PANACEA [46] (Table 1).